300 episodes

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

GRACEcast Lung Cancer Video cancerGRACE - H. Jack West, MD

    • Science

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

    • video
    Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

    Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

    Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

    • 4 min
    • video
    Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

    Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

    The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

    • 5 min
    • video
    Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

    Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

    Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

    • 2 min
    • video
    Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

    Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

    The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

    • 7 min
    • video
    Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

    Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

    The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

    • 7 min
    • video
    What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

    What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

    "Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

    • 3 min

Top Podcasts In @@categoryName@@

GRACEcast Cancer 101 Video
cancerGRACE - H. Jack West, MD
GRACEcast Head and Neck Cancer Video NEW
cancerGRACE - H. Jack West, MD
GRACEcast Bladder Cancer Video
cancerGRACE - H. Jack West, MD
GRACEcast Cancer 101 Audio
cancerGRACE - H. Jack West, MD
GRACEcast Kidney Cancer Video
cancerGRACE - H. Jack West, MD
GRACEcast Pancreatic Cancer Video
cancerGRACE - H. Jack West, MD